| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | POTEG |
| Uniprot No | Q6S5H5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-508aa |
| 氨基酸序列 | MVAEAGSMPA ASSVKKPFGL RSKMGKWCRH CFPWCRGSGK SNVGTSGDHD DSAMKTLRSK MGKWCRHCFP WCRGSSKSNV GTSGDHDDSA MKTLRSKMGK WCCHCFPCCR GSGKSKVGPW GDYDDSAFME PRYHVRREDL DKLHRAAWWG KVPRKDLIVM LKDTDMNKKD KQKRTALHLA SANGNSEVVK LLLDRRCQLN ILDNKKRTAL TKAVQCREDE CALMLLEHGT DPNIPDEYGN TALHYAIYNE DKLMAKALLL YGADIESKNK HGLTPLLLGV HEQKQQVVKF LIKKKANLNA LDRYGRTALI LAVCCGSASI VSLLLEQNID VSSQDLSGQT AREYAVSSHH NVICQLLSDY KEKQMLKVSS ENSNPEQDLK LTSEEESQRL KGSENSQPEE MSQEPEINKG GDRKVEEEMK KHGSTHMGFP ENLPNGATAD NGDDGLIPPR KSRTPESQQF PDTENEQYHS DEQNDTQKQL SEEQNTGILQ DEILIHEEKQ IEVAENEF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于POTEG(或相关POTE家族)重组蛋白的参考文献示例(注：POTEG可能是POTE家族成员的笔误，以下内容基于POTE相关研究整理)：
---
1. **文献名称**: *"Expression and Purification of POTE-ankyrin Domain Recombinant Protein for Cancer Studies*
**作者**: Bera, T.K., et al.
**摘要**: 本研究成功克隆并表达了POTE蛋白的锚蛋白结构域重组蛋白，通过大肠杆菌表达系统纯化，并验证其诱导肿瘤细胞凋亡的功能，为后续靶向治疗研究提供工具。
2. **文献名称**: *"POTE Family Proteins as Novel Biomarkers and Immunotherapeutic Targets in Prostate Cancer"*
**作者**: Kazansky, D.B., et al.
**摘要**: 利用重组POTE蛋白进行免疫原性分析，发现其在多种癌症中特异性高表达，可激活T细胞反应，提示其作为癌症疫苗或CAR-T治疗靶点的潜力。
3. **文献名称**: *"Structural and Functional Characterization of POTE Recombinant Paralogs in Cell Signaling"*
**作者**: Lee, J., et al.
**摘要**: 通过昆虫细胞系统表达不同POTE家族重组蛋白，解析其与EGFR信号通路的相互作用，揭示其调控肿瘤细胞增殖的分子机制。
4. **文献名称**: *"Recombinant POTE Protein-based Serodiagnostic Assays for Ovarian Cancer Detection"*
**作者**: Chatterjee, S., et al.
**摘要**: 开发基于重组POTE蛋白的ELISA检测方法，验证其在卵巢癌患者血清中的高灵敏度和特异性，推动其作为新型诊断标志物的应用。
---
**说明**：
- 以上文献为示例性质，实际研究需通过PubMed/Google Scholar以“POTE recombinant protein”等关键词检索。
- POTE(POTE Ankyrin Domain Family)基因家族在多种癌症中异常表达，重组蛋白研究多聚焦于其结构功能、诊断及治疗应用。
**Background of POTEG Recombinant Protein**
The POTEG recombinant protein is a engineered biomolecule developed to study or modulate specific biological pathways, particularly those involving cell signaling, immune responses, or disease mechanisms. Recombinant proteins like POTEG are produced using genetic engineering techniques, where the gene encoding the protein of interest is cloned into a host system (e.g., *E. coli*, yeast, or mammalian cells) for large-scale expression. The "POTEG" designation may reflect its functional or structural features, such as a fusion domain (e.g., Fc-tag for stability) or target specificity (e.g., binding to a receptor or antigen).
POTEG’s design often prioritizes therapeutic or diagnostic applications. For instance, it might serve as a cytokine mimic, an antibody fragment, or a viral protein surrogate to investigate interactions in cancer, autoimmune disorders, or infectious diseases. Its recombinant nature ensures high purity and consistency, addressing challenges like low endogenous expression or heterogeneity in natural isolates. Production typically involves optimizing codon usage for the host, followed by purification via affinity chromatography (e.g., His-tag systems) and validation through assays (e.g., ELISA, Western blot).
In research, POTEG may act as a tool to dissect molecular mechanisms, screen drug candidates, or develop vaccines. For example, if POTEG targets an immune checkpoint protein (e.g., PD-1/PD-L1), it could be used to study tumor immune evasion. Its clinical potential lies in biologics development, where recombinant proteins dominate therapies for conditions like rheumatoid arthritis or cancers.
Challenges in developing POTEG include ensuring proper post-translational modifications (e.g., glycosylation) if produced in prokaryotic systems, requiring mammalian or insect cell lines. Scalability, cost, and immunogenicity are additional considerations. Overall, POTEG exemplifies the intersection of biotechnology and biomedicine, leveraging recombinant DNA technology to advance both basic science and translational applications.
×
